PEOPLE WITH THE SKIN CONDITION KNOWN AS MODERATE-TO-SEVERE PLAQUE PSORIASIS NOW HAVE A NEW Rx TREATMENT OPTION

Listen to “PEOPLE WITH THE SKIN CONDITION KNOWN AS MODERATE-TO-SEVERE PLAQUE PSORIASIS NOW HAVE A NEW Rx TREATMENT OPTION” on Spreaker.

The FDA Recently Approved a New Oral Treatment

There is now a new treatment option for the estimated 2 million people in the United States living with moderate-to-severe plaque psoriasis1,2,3 whose symptoms may make day-to-day life more challenging. For those that aren’t familiar with psoriasis, it is a widely prevalent, chronic, systemic immune-mediated disease.4

And up to 90% of patients with psoriasis have psoriasis vulgaris, also known as plaque psoriasis,5 which is characterized by distinct round or oval plaques typically covered by silvery-white scales.

One of the challenges that both doctors and patients face is that despite the availability of therapies, many people living with plaque psoriasis in the United States are untreated or undertreated.5,6

But good news has arrived. The U.S. Food and Drug Administration (FDA) has officially approved a new treatment for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Dr. April Armstrong, dermatologist and clinical investigator in one of the treatment’s trials and Associate Dean and Professor of Dermatology at the University of Southern California, alongside Leah M. Howard, J.D., President and CEO of the National Psoriasis Foundation, will discuss the impact of psoriasis and a new, FDA-approved oral treatment for moderate-to-severe plaque psoriasis. *

*Dr. April Armstrong and Leah Howard are paid spokespeople and are being compensated for their time.

Interview is courtesy: Bristol Myers Squibb

1. Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol.2021;157(8):940-946. doi:10.1001/jamadermatol.2021.2007

2 Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945-1960. doi:10.1001/jama.2020.4006

3 Armstrong et al. Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States: Findings From the National Psoriasis Foundation Surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180–1185.
4. Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PloS One. 2012;7(12):e52935.

5. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May;58(5):826-50.

6. Lebwohl M, Langley RG, Paul C, et al. Evolution of patient perceptions of psoriatic disease: results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey. Dermatol Ther (Heidelb). 2022;12(1):61-78. doi:10.1007/s13555-021-00635-4

#aprilarmstrong #leahhoward #plaquepsoriasis #psoriasis #treatment #immunedisease #prevalent #chronic #systemicdisease #clinicaltreatment